IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+11.33%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$1.07B
AUM Growth
+$1.07B
(+19%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
9.88%
Top 10 Holdings %
Top 10 Hldgs %
45.5%
Holding
98
New
18
Increased
24
Reduced
16
Closed
24
Top Buys
| 1 |
Quest Diagnostics
DGX
|
$26.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$26.3M |
| 3 |
Cardinal Health
CAH
|
$23.5M |
| 4 |
Eli Lilly
LLY
|
$19.5M |
| 5 |
Charles River Laboratories
CRL
|
$17.4M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$19.6M |
| 2 |
Ascendis Pharma
ASND
|
$15.6M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$12.8M |
| 4 |
Krystal Biotech
KRYS
|
$10.8M |
| 5 |
Boston Scientific
BSX
|
$10.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Bristol-Myers Squibb
BMY
$96.7B
| – | – |
-100,000
| Closed | -$6.1M |
|
77
BioNTech
BNTX
$24.1B
| – | – |
-40,000
| Closed | -$3.64M |
|
|
BPMC
78
DELISTED
Blueprint Medicines
BPMC
| – | – |
-145,000
| Closed | -$12.8M |
|
79
Cabaletta Bio
CABA
$144M
| – | – |
-850,000
| Closed | -$1.18M |
|
80
Cigna
CI
$80.2B
| – | – |
-10,000
| Closed | -$3.29M |
|
81
Crinetics Pharmaceuticals
CRNX
$3.26B
| – | – |
-125,000
| Closed | -$4.19M |
|
82
Dyne Therapeutics
DYN
$1.92B
| – | – |
-450,000
| Closed | -$4.71M |
|
83
Fate Therapeutics
FATE
$119M
| – | – |
-700,000
| Closed | -$553K |
|
|
84
Gilead Sciences
GILD
$140B
| – | – |
-175,000
| Closed | -$19.6M |
|
85
Globus Medical
GMED
$7.94B
| – | – |
-50,000
| Closed | -$3.66M |
|
86
IQVIA
IQV
$31.4B
| – | – |
-30,000
| Closed | -$5.29M |
|
|
87
Krystal Biotech
KRYS
$4.35B
| – | – |
-60,000
| Closed | -$10.8M |
|
88
Labcorp
LH
$22.8B
| – | – |
-20,000
| Closed | -$4.65M |
|
89
Masimo
MASI
$7.43B
| – | – |
-45,000
| Closed | -$7.5M |
|
|
MREO
90
Mereo BioPharma
MREO
$275M
| – | – |
-800,000
| Closed | -$1.8M |
|
91
PTC Therapeutics
PTCT
$4.41B
| – | – |
-100,000
| Closed | -$5.1M |
|
|
PTN
92
DELISTED
Palatin Technologies
PTN
| – | – |
-1,000,000
| Closed | -$583K |
|
93
Repligen
RGEN
$6.54B
| – | – |
-20,000
| Closed | -$2.54M |
|
94
Avidity Biosciences
RNA
$6.12B
| – | – |
0
| – | – |
|
95
Teva Pharmaceuticals
TEVA
$21.5B
| – | – |
-500,000
| Closed | -$7.69M |
|
96
Viking Therapeutics
VKTX
$3.02B
| – | – |
0
| – | – |
|
97
Verastem
VSTM
$585M
| – | – |
-500,000
| Closed | -$3.02M |
|
98
Xenon Pharmaceuticals
XENE
$2.99B
| – | – |
0
| – | – |
|